To analyze the dosimetric consequences and acute toxicities associated with the routine injection of a bioabsorbable hydrogel spacer in the perirectal space during permanent low dose rate prostate brachytherapy. Materials/Methods: A consecutive series of 80 patients implanted with I-125 permanent brachytherapy seeds between August 2013 and October 2014 were evaluated. The most recent 40 patients also underwent a single transperineal injection of polyethylene glycol (5 cc) in the space between the prostate and rectum. This was performed immediately after the implant following hydrodissection of Denonvilliers' fascia with 1-3 cc of radiopaque IV contrast. Postop day 0 CT-based dosimetry was compared between patients with and without hydrogel spacer to evaluate for differences in rectal and prostate dosimetry using a two-tailed unequal variance t-test. Results: There were no differences between baseline factors with regards to mean age (63 years), pre-implant gland size (30 cc), number of seeds implanted (64), or total activity (25 mCi). There were no acute genitourinary or rectal toxicities within the first 3 months that could be attributed to the hydrogel rectal spacer. Comparing patients with and without hydrogel, the mean separation between the prostate and rectum was 14 mm AE 4 mm versus 6 mm AE 3 mm (P<0.0001), respectively. The mean rectal doses to 1 cc, 2 cc, and 5 cc relative to prescription dose were 41% vs 61% (P<0.0001), 44% vs 50% (P<0.0001), and 26% vs 32% (P<0.0009) respectively. There were no statistically significant differences on prostate coverage with or without a hydrogel rectal spacer with V100: 92% vs 91%, V150: 45% vs 48%, D90: 106% vs 106%, respectively. Conclusion: The use of PEG hydrogel significantly and consistently reduced the rectal exposure of radiation in patients undergoing permanent brachytherapy without any adverse effect on acute toxicity or prostate gland coverage. Purpose/Objective(s): Given the rapid adoption of stereotactic body radiation therapy (SBRT), it is unclear if prior models using conventionally fractionated radiation therapy adequately predict sexual function given the unique radiobiology of SBRT. Herein, we analyze a large prospective cohort of men with prostate cancer treated definitively with SBRT and to assess sexual function longitudinally. androgen deprivation therapy (ADT) for 3-6 months were given at the discretion of the treating physician generally for higher risk patients. Potency was defined as the patient reported answer of having erections "firm enough for intercourse" irrespective of using sexual aids. Potency was assessed serially at baseline, 3-, 6-, 12-, 24-, and 36-months. Predictors of potency were assessed using univariable and multivariable logistical regression analyses. Results: The median follow-up of the cohort was 3-years. The mean age was 69 years old, and 24%, 57%, and 19% were low, intermediate, and high risk by NCCN, respectively. For patients who were potent at baseline (n Z 328), 36-months post-SBRT 76% maintained a high level of sexual HRQOL (score of !75 out of 100) and 61% retained potency. Multivariate logistic regression analyses for potency preservation are detailed in Table 1 . Age and pretreatment sexual HRQOL predicted long-term potency at all-time points. Use of ADT was significantly associated with a decline in potency only at 3-and 6-months post-SBRT. Higher dose (Dose level 2) predicted for worse long-term potency beginning 12-months through 36-months post-SBRT. Conclusion: Multiple factors predict sexual potency following SBRT treatment for prostate cancer. At all-time points, younger men and those with high baseline sexual HRQOL are more likely to retain potency. In contrast, short-term ADT transiently impacts potency up to 6-months post-SBRT, while the late effects of dose escalation impact potency 12-months and beyond without signs of improvement for at least 3-years after SBRT. SBRT dose escalation beyond 36.25 Gy in 5 fractions should be studied further to evaluate the impact on long-term sexual function. 
Purpose/Objective(s): Given the rapid adoption of stereotactic body radiation therapy (SBRT), it is unclear if prior models using conventionally fractionated radiation therapy adequately predict sexual function given the unique radiobiology of SBRT. Herein, we analyze a large prospective cohort of men with prostate cancer treated definitively with SBRT and to assess sexual function longitudinally. Materials/Methods: Between January 2008 and September 2014, 720 men were consecutively treated with SBRT at a single institution. Health related quality of life (HRQOL) data were collected prospectively via the Expanded Prostate Cancer Index Composite (EPIC-26). Patients were treated with 35-36.25 Gy in 5 fractions (Dose level 1) or 19.5 Gy in 3 fractions in combination with supplemental radiation therapy to 45-50.4 Gy in 1.8 Gy fractions (Dose level 2). Dose level 2 and neoadjuvant androgen deprivation therapy (ADT) for 3-6 months were given at the discretion of the treating physician generally for higher risk patients. Potency was defined as the patient reported answer of having erections "firm enough for intercourse" irrespective of using sexual aids. Potency was assessed serially at baseline, 3-, 6-, 12-, 24-, and 36-months. Predictors of potency were assessed using univariable and multivariable logistical regression analyses. Results: The median follow-up of the cohort was 3-years. The mean age was 69 years old, and 24%, 57%, and 19% were low, intermediate, and high risk by NCCN, respectively. For patients who were potent at baseline (n Z 328), 36-months post-SBRT 76% maintained a high level of sexual HRQOL (score of !75 out of 100) and 61% retained potency. Multivariate logistic regression analyses for potency preservation are detailed in Table 1 . Age and pretreatment sexual HRQOL predicted long-term potency at all-time points. Use of ADT was significantly associated with a decline in potency only at 3-and 6-months post-SBRT. Higher dose (Dose level 2) predicted for worse long-term potency beginning 12-months through 36-months post-SBRT. Conclusion: Multiple factors predict sexual potency following SBRT treatment for prostate cancer. At all-time points, younger men and those with high baseline sexual HRQOL are more likely to retain potency. In contrast, short-term ADT transiently impacts potency up to 6-months post-SBRT, while the late effects of dose escalation impact potency 12-months and beyond without signs of improvement for at least 3-years after SBRT. SBRT dose escalation beyond 36.25 Gy in 5 fractions should be studied further to evaluate the impact on long-term sexual function. 
